Clinical trial • Phase I • Neurology
Clinical trial in Alzheimer's disease
Phase I trial for Alzheimer's disease. 45 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Alzheimer's disease
- Trial Stage
- Phase I
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 23-06-2025
- First CTIS Authorization Date
- 05-12-2025
Trial design
Phase I trial across 3 sites in Sweden.
- Target Sample Size
- 45
Eligibility
Recruits 45 Vulnerable population not selected; no details on consent or assent available in the CTIS record..
- Vulnerable Population
- Vulnerable population not selected; no details on consent or assent available in the CTIS record.
Recruitment
- Planned Sample Size
- 45
- Recruitment Window Months
- 7
- Consent Approach
- Not specified in the CTIS record.
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 45
Sweden
- Earliest CTIS Part Ii Submission Date
- 28-11-2025
- Latest Decision Or Authorization Date
- 18-03-2026
- Processing Time Days
- 110
- Number Of Sites
- 3
- Number Of Participants
- 45
Sites
- Site Name
- CTC Clinical Trial Consultants AB (Karolinska Vagen 22)
- Department Name
- CTC Clinical Trial Consultants AB
- Contact Person Name
- Kaveh Azizi
- Contact Person Email
- kaveh.azizi@ctc-ab.se
- Site Name
- Karolinska Institutet (Alfred Nobels Alle 8, Flemingsberg)
- Department Name
- Department of Neurobiology, Care Sciences and Society
- Contact Person Name
- Agneta Nordberg
- Contact Person Email
- agneta.k.nordberg@ki.se
- Site Name
- Karolinska Institutet (Nobels Vag 6)
- Department Name
- Clinical Neuroscience
- Contact Person Name
- Per Stenkrona
- Contact Person Email
- per.stenkrona@ki.se
Sponsor
Primary sponsor
- Full Name
- Karolinska Institutet
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Sweden
Related trials
Other published trials that may interest you.